Loading patent…
AssigneeDeutsches Krebsforschungszentrum Stiftung des Offentlichen Rechts
InventorsVolker Schirrmacher, Philipp Beckhove, Philippe Fournier, Maximilian Aigner
Estimating the term…
The present invention relates to an antibody fusion protein which specifically recognizes the VA, HN or F surface antigen of the New Castle Disease Virus (NDV), a surface molecule of a tumor-unspecific T cell or a surface molecule of a dendritic cell and an immunocytokine. Also encompassed by the present invention are polynucleotides encoding the aforementioned antibody fusion protein as well as tumor-unspecific key cells or dendritic cells bound by the antibody fusion protein. Moreover, the present invention relates to a method of treating a tumor in a subject comprising administering to the said subject the antibody fusion protein, the tumor-unspecific T cell, the dendritic cell or the polynucleotide of the invention. Preferably, the said tumor is a solid tumor.
An antibody fusion protein which specifically recognizes
A method of treating a tumor in a subject comprising administering to the subject suffering from the said tumor in a therapeutically effective amount (a) an antibody fusion protein which specifically recognizes (i) the VA, HN or F surface antigen of the New Castle Disease Virus (NDV) and (ii) a surface molecule of a tumor-unspecific T cell or a surface molecule of a dendritic cell, (b) a polynucleotide encoding said antibody fusion protein, (c) a tumor-unspecific T cell bound by the antibody fusion protein, or (d) a dendritic cell bound by the antibody fusion protein.
Dependencies are inferred from the claim text.